EA201491496A1 - Ингибиторы c-концевого домена hsp90 - Google Patents

Ингибиторы c-концевого домена hsp90

Info

Publication number
EA201491496A1
EA201491496A1 EA201491496A EA201491496A EA201491496A1 EA 201491496 A1 EA201491496 A1 EA 201491496A1 EA 201491496 A EA201491496 A EA 201491496A EA 201491496 A EA201491496 A EA 201491496A EA 201491496 A1 EA201491496 A1 EA 201491496A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hsp90
end domain
domain inhibitors
inhibitors
compounds
Prior art date
Application number
EA201491496A
Other languages
English (en)
Other versions
EA027147B1 (ru
Inventor
Брайан С. Дж. Благг
Бхаскар Редди Кусума
Тизер Сандстром
Original Assignee
Юниверсити Оф Канзас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Канзас filed Critical Юниверсити Оф Канзас
Publication of EA201491496A1 publication Critical patent/EA201491496A1/ru
Publication of EA027147B1 publication Critical patent/EA027147B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Предложены ингибиторы С-концевых Hsp90 и фармацевтические композиции, содержащие такие соединения. Соединения по описанию могут быть использованы для лечения и/или предотвращения нейродегенеративных расстройств, таких как диабетическая периферическая нейропатия.
EA201491496A 2012-02-09 2013-02-08 Ингибиторы c-концевого домена hsp90 EA027147B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597004P 2012-02-09 2012-02-09
PCT/US2013/025387 WO2013119985A1 (en) 2012-02-09 2013-02-08 C-terminal hsp90 inhibitors

Publications (2)

Publication Number Publication Date
EA201491496A1 true EA201491496A1 (ru) 2015-01-30
EA027147B1 EA027147B1 (ru) 2017-06-30

Family

ID=47754998

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491496A EA027147B1 (ru) 2012-02-09 2013-02-08 Ингибиторы c-концевого домена hsp90

Country Status (24)

Country Link
US (5) US9422320B2 (ru)
EP (2) EP3656758B1 (ru)
JP (1) JP6121450B2 (ru)
KR (1) KR102124109B1 (ru)
CN (2) CN104271587B (ru)
AU (1) AU2013216858C1 (ru)
BR (1) BR112014019704B1 (ru)
CA (1) CA2866814C (ru)
CY (1) CY1122358T1 (ru)
DK (2) DK2812341T3 (ru)
EA (1) EA027147B1 (ru)
ES (1) ES2755093T3 (ru)
FI (1) FI3656758T3 (ru)
HK (2) HK1205131A1 (ru)
HR (1) HRP20191940T1 (ru)
HU (1) HUE046939T2 (ru)
LT (2) LT2812341T (ru)
MX (1) MX361233B (ru)
NZ (1) NZ629778A (ru)
PL (2) PL2812341T3 (ru)
PT (2) PT3656758T (ru)
RS (2) RS59719B1 (ru)
SI (1) SI2812341T1 (ru)
WO (1) WO2013119985A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2812341T3 (pl) 2012-02-09 2020-03-31 The University Of Kansas Inhibitory C-końcowe HSP90
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
CN106536498A (zh) 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
WO2016145219A1 (en) * 2015-03-10 2016-09-15 University Of Florida Research Foundation, Inc. Treatment of peripheral neuropathies
KR20200141985A (ko) * 2018-02-07 2020-12-21 리아타 파마슈티컬즈, 아이엔씨. 노보비오신 유사체 및 프롤린의 공-결정 형태
IL278698B2 (en) 2018-05-14 2024-06-01 Reata Pharmaceuticals Inc Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608594B2 (en) 2004-11-03 2009-10-27 University Of Kansas Novobiocin analogues as anticancer agents
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
WO2007095586A2 (en) * 2006-02-14 2007-08-23 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8044041B2 (en) 2006-11-15 2011-10-25 Forest Laboratories Holdings Limited Phthalazine derivatives as inhibitors of protein kinase
CA2680778C (en) 2007-03-20 2016-05-10 Curis, Inc. Fused amino pyridine as hsp90 inhibitors
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP5766617B2 (ja) 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
WO2011041593A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
WO2012008435A1 (ja) 2010-07-13 2012-01-19 大日本住友製薬株式会社 ビアリールアミド誘導体またはその薬理学的に許容される塩
CN101967125B (zh) * 2010-10-08 2012-07-04 广州暨南生物医药研究开发基地有限公司 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
PL2812341T3 (pl) 2012-02-09 2020-03-31 The University Of Kansas Inhibitory C-końcowe HSP90
AU2014346483B2 (en) 2013-11-07 2019-01-17 The University Of Kansas Biphenylamide derivative Hsp90 inhibitors
AU2014346368B2 (en) 2013-11-11 2019-03-14 The University Of Kansas Coumarin based Hsp90 inhibitors with urea and ether substituents
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
CN106536498A (zh) 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺

Also Published As

Publication number Publication date
CA2866814C (en) 2021-02-16
US20230102047A1 (en) 2023-03-30
US20210188891A1 (en) 2021-06-24
EP2812341B1 (en) 2019-08-28
NZ629778A (en) 2016-03-31
PL2812341T3 (pl) 2020-03-31
LT2812341T (lt) 2019-12-10
KR102124109B1 (ko) 2020-06-17
DK3656758T3 (da) 2024-04-22
US9422320B2 (en) 2016-08-23
FI3656758T3 (fi) 2024-04-22
EP2812341A1 (en) 2014-12-17
US11390640B2 (en) 2022-07-19
HUE046939T2 (hu) 2020-04-28
JP6121450B2 (ja) 2017-04-26
MX361233B (es) 2018-11-30
MX2014009608A (es) 2015-05-20
KR20150001729A (ko) 2015-01-06
US20170051000A1 (en) 2017-02-23
BR112014019704A2 (ru) 2017-06-20
CA2866814A1 (en) 2013-08-15
HK1249519A1 (zh) 2018-11-02
US20190023730A1 (en) 2019-01-24
US10030041B2 (en) 2018-07-24
RS65412B1 (sr) 2024-05-31
US20150057240A1 (en) 2015-02-26
BR112014019704A8 (pt) 2017-07-11
AU2013216858A1 (en) 2014-09-18
CN107474085A (zh) 2017-12-15
EP3656758A1 (en) 2020-05-27
HK1205131A1 (en) 2015-12-11
JP2015506982A (ja) 2015-03-05
ES2755093T3 (es) 2020-04-21
BR112014019704B1 (pt) 2022-05-31
CY1122358T1 (el) 2021-01-27
AU2013216858C1 (en) 2018-03-01
AU2013216858B2 (en) 2017-08-24
PT2812341T (pt) 2019-11-22
EP3656758B1 (en) 2024-03-06
US10882881B2 (en) 2021-01-05
CN104271587B (zh) 2017-09-12
LT3656758T (lt) 2024-05-10
HRP20191940T1 (hr) 2020-01-10
US20200283465A1 (en) 2020-09-10
US10590157B2 (en) 2020-03-17
EA027147B1 (ru) 2017-06-30
CN107474085B (zh) 2021-05-11
RS59719B1 (sr) 2020-01-31
CN104271587A (zh) 2015-01-07
SI2812341T1 (sl) 2020-02-28
WO2013119985A1 (en) 2013-08-15
PL3656758T3 (pl) 2024-06-10
PT3656758T (pt) 2024-03-27
DK2812341T3 (da) 2019-11-18

Similar Documents

Publication Publication Date Title
EA201890315A1 (ru) Молекулы антител, связывающие cd22
CY1122796T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων
AU2016204248A1 (en) Boron-Containing Molecules
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
EA201592143A1 (ru) Новые бициклические ингибиторы бромодомена
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201490806A1 (ru) Комбинированный состав двух противовирусных соединений
EA202193044A2 (ru) Способы лечения таупатии
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
WO2014062733A3 (en) Substituted benzene compounds
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
IN2015DN03029A (ru)
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201590887A1 (ru) Композиция
EA201690159A1 (ru) Способы и композиции для лечения рака
EA201490688A1 (ru) 2-тиопиримидиноны
BR112014025041B8 (pt) Composição farmacêutica
EA201491496A1 (ru) Ингибиторы c-концевого домена hsp90